Register
Forgot your password?

Evaluation of the efficacy and safety of direct oral anticoagulants in patients with atrial fibrillation in the perioperative and long-term periods after catheter ablation

Authors: Gyulmamedova S.M., Berdibekov B.Sh., Bulaeva N.I., Ryzhova T.S., Kabisova A.K., Golukhova Е.Z.

Company: Bakoulev National Medical Research Center for Cardiovascular Surgery, Moscow, Russian Federation

For correspondence:  Sign in or register.

Type:  Original articles


DOI: https://doi.org/10.24022/1997-3187-2025-19-4-432-444

For citation: Gyulmamedova S.M., Berdibekov B.Sh., Bulaeva N.I., Ryzhova T.S., Kabisova A.K., Golukhova Е.Z. Evaluation of the efficacy and safety of direct oral anticoagulants in patients with atrial fibrillation in the perioperative and long-term periods after catheter ablation. Creative Cardiology. 2025; 19 (4): 432–444 (in Russ.). DOI: 10.24022/1997-3187-2025-19-4-432-444

Received / Accepted:  08.09.2025 / 22.09.2025

Keywords: atrial fibrillation direct oral anticoagulants apixaban dabigatran rivaroxaban efficacy safety catheter ablation

Download
Full text:  

 

Abstract

Objective. To conduct a comprehensive assessment of the efficacy and safety of direct oral anticoagulants (DOACs) in patients with atrial fibrillation (AF) at different stages of catheter ablation (CA).

Material and methods. In a single-center bidirectional study conducted between 2016 and 2024, two patient cohorts were formed: a retrospective cohort (n=1005) for the analysis of perioperative outcomes and a prospective cohort (n=597) for the evaluation of long-term results. In the retrospective sample, apixaban was prescribed to 382 patients, rivaroxaban to 492, and dabigatran to 131, whereas in the prospective cohort these numbers were 246, 279, and 51, respectively. The mean age of patients in the retrospective and prospective cohorts was comparable: 59.8±10.6 and 58.5±10.8 years, respectively. The median follow-up in the long-term period was 23.0 [11.0; 38.0] months. The primary composite endpoint included all-cause mortality, cardiac death, thromboembolic events (TEEs), left atrial appendage thrombosis, and ischemic events. Safety outcomes were assessed by the incidence of bleeding, classified according to the International Society on Thrombosis and Haemostasis (ISTH) criteria, as well as procedure- and access site-related complications.

Results. No major TEEs were observed in the perioperative period; bleeding events were extremely rare, with only one minor bleeding episode registered in the rivaroxaban group (0.2%), with no statistically significant differences between groups (p=0.99). In the early postoperative period, the incidence of bleeding was 1.0% with apixaban, 1.2% with rivaroxaban, and 3.1% with dabigatran; between-group differences did not reach statistical significance (p=0.093). However, post-puncture hematomas occurred significantly more often in patients receiving dabigatran (1.5%) compared with apixaban and rivaroxaban, where no such complications were observed (p=0.017). During long-term follow- up, two thromboembolic events were recorded: one ischemic stroke after DOAC discontinuation and one transient ischemic attack in a patient on dabigatran 150 mg/day with concomitant hematuria. The incidence of any bleeding was significantly higher with dabigatran compared to rivaroxaban and apixaban (5.9, 0.7, and 0%, respectively; p=0.003). Similarly, minor bleedings were significantly more frequent with dabigatran compared to rivaroxaban and apixaban (3.9%, 0.7%, and 0%, respectively; p=0.022). Major bleeding occurred only in the dabigatran group (2.0%), although the difference did not reach statistical significance (p=0.089).

Conclusion. The use of DOACs in patients with AF undergoing CA ensures effective prevention of TEEs with a low incidence of bleeding. Among the studied agents, apixaban demonstrated the most favorable safety profile throughout all follow-up stages, rivaroxaban provided comparable efficacy, whereas dabigatran was associated with a higher rate of hemorrhagic complications, particularly in the long-term period. These findings emphasize the importance of personalized anticoagulant therapy selection based on individual bleeding risk and patient clinical profile.

References

  1. Samim D., Choffat D., Vollenweider P., Waeber G., Marques-Vidal P., Méan M. Prevalence of atrial fibrillation. Herz. 2023; 48 (1): 48–54. DOI: 10.1007/s00059-021-05090-7
  2. Golukhova E.Z., Milievskaya E.B., Filatov A.G., Semenov V.Yu., Pryanishnikov V.V., Serguladze S.Yu. Heart rhythm and conduction disorders. Moscow; 2024 (in Russ.).
  3. Avanesyan G.A., Filatov A.G., Shalov R.Z. Atrial fibrillation in young patients. Annaly Aritmologii. 2024; 21 (2): 122–134 (in Russ.). DOI: 10.15275/annaritmol.2024.2.7
  4. Minaev A.V., Mironenko M.Y., Dontsova V.I., Pirushkina Y.D., Berdibekov B.S., Voynov A.S. et al. Left atrial structural and functional changes in adults with congenital septal defects and paroxysmal atrial fibrillation. J. Clin. Med. 2024; 13: 6023. DOI: 10.3390/jcm13196023
  5. Golukhova E.Z. Report on the clinical and scientific activity of Bakoulev National Medical Research Center for Cardiovascular Surgery for 2024. Development prospects. The Bulletin of Bakoulev Center. Cardiovascular Diseases. 2025; 26 (Special Issue): 5–130 (in Russ.). DOI: 10.24022/1810-0694-2025-26S
  6. Gyulmamedova S.M., Berdibekov B.Sh., Bulaeva N.I., Serguladze S.Yu., Filatov A.G., Golukhova Е.Z. Long-term results of the effectiveness of cryoballoon and radiofrequency ablation in patients with atrial fibrillation: propensity score matching analysis. Kardiologiia. 2025; 65 (8): 3–11 (in Russ.). DOI: 10.18087/cardio.2025.8.n3001
  7. Ko D., Chung M.K., Evans P.T., Benjamin E.J., Helm R.H. Atrial fibrillation: a review. JAMA. 2025; 333 (4): 329–342. DOI: 10.1001/jama.2024.22451
  8. Gyulmamedova S.M., Bulaeva N.I., Kubova М.Ch. The role of direct oral anticoagulants in the treatment of patients with non-valvular atrial fibrillation. Creative Cardiology. 2023; 17 (3): 350–358 (in Russ.). DOI: 10.24022/1997-3187-2023-17-3-350-358
  9. Zeng S., Zheng Y., Jiang J., Ma J., Zhu W., Cai X. Effectiveness and safety of DOACs vs. warfarin in patients with atrial fibrillation and frailty: a systematic review and meta-analysis. Front. Cardiovasc. Med. 2022; 9: 907197. DOI: 10.3389/fcvm.2022.907197
  10. Waranugraha Y., Rizal A., Syaban M.F.R., Faratisha I.F.D., Erwan N.E., Yunita K.C. Direct comparison of non-vitamin K antagonist oral anticoagulant versus warfarin for stroke prevention in non-valvular atrial fibrillation: a systematic review and meta-analysis of real-world evidences. Egypt. Heart J. 2021; 73 (1): 1–17. DOI: 10.1186/s43044-021-00194-1
  11. Talmor-Barkan Y., Yacovzada N.-S., Rossman H., Witberg G., Kalka I., Kornowski R. et al. Head-to-head efficacy and safety of rivaroxaban, apixaban, and dabigatran in an observational nationwide targeted trial. Eur. Heart J. Cardiovasc. Pharmacother. 2022; 9 (1): 26–37. DOI:10.1093/ehjcvp/pvac063
  12. Trujillo T.C., Dobesh P.P., Crossley G.H., Finks S.W. Contemporary management of direct oral anticoagulants during cardioversion and ablation for nonvalvular atrial fibrillation. Pharmacotherapy. 2019; 39 (1): 94–108. DOI: 10.1002/phar.2205
  13. Fomina D.S., Filatov A.G., Shalov R.Z. Influence of left atrial and pulmonary vein anatomy on atrial fibrillation. Annaly Aritmologii. 2024; 21(3): 184–189 (in Russ.). DOI: 10.15275/annaritmol.2024.3.6
  14. Tarashvili E.G., Stupakov S.I. Indications for catheter ablation for atrial fibrillation: comparison of clinical recommendations from different countries. Annaly Aritmologii. 2024; 21 (2): 113–121 (in Russ.). DOI: 10.15275/annaritmol.2024.2.6
  15. Cappato R., Levy S., Providencia R., Ali H., Ardashev A., Barra S. et al. Concise guidelines of the European Cardiac Arrhythmias Society (ECAS) on “catheter ablation of atrial fibrillation”: A prepublication of the methods in preparation of the final guidel ines document. J. Cardiovasc. Electrophysiol. 2024; 35 (7): 18–24. DOI: 10.1111/jce.16254
  16. Coppola G., Corrado E., Luparelli M., Manno G., Mignano A., Ciaramitaro G. et al. Direct oral anticoagulants in the setting of catheter ablation of atrial fibrillation: state of art. Curr. Probl. Cardiol. 2021; 46 (3): 100622. DOI: 10.1016/j.cpcardiol.2020.100622
  17. Grymonprez M., De Backer T.L., Bertels X., Steurbaut S., Lahousse L. Long-term comparative effectiveness and safety of dabigatran, rivaroxaban, apixaban and edoxaban in patients with atrial fibrillation: a nationwide cohort study. Front. Pharmacol. 2023; 14: 1125576. DOI: 10.3389/fphar.2023.1125576
  18. Menichelli D., Del Sole F., Di Rocco A., Farcomeni A., Vestri A., Violi F. et al. Real-world safety and efficacy of direct oral anticoagulants in atrial fibrillation: a systematic review and meta-analysis of 605 771 patients. Eur. Heart J. Cardiovasc. Pharmacother. 2021; 7 (FI1): f11–9. DOI: 10.1093/ehjcvp/pvab002
  19. Silverio A., Di Maio M., Prota C., De Angelis E., Radano I., Citro R. et al. Safety and efficacy of non-vitamin K antagonist oral anticoagulants in elderly patients with atrial fibrillation: systematic review and meta-analysis of 22 studies and 440 281 patients. Eur. Heart J. Cardiovasc. Pharmacother. 2021; 7 (FI1): f20–29. DOI: 10.1093/ehjcvp/pvz073
  20. Golukhova E. Z., Keren M.A., Zavalikhina T. V., Bulaeva N. I., Akatov D. S., Sigaev I. Yu. et al. Potential of machine learning methods in operational risk stratification in patients with coronary artery disease scheduled for coronary bypass surgery. Russian Journal of Cardiology. 2023; 28 (2): 5211 (in Russ.). DOI: 10.15829/1560-4071-2023-5211
  21. Sigaev I.Yu., Kudashev I.F., Keren M.A., Kazaryan A.V., Starostin M.V., Morchadze B.D. Determinations of the optimal surgical treatment simultaneous operations perform of carotid endarterectomy and coronary artery bypass grafting in the aspect of reducing the incidence of neurological complications. Clinical Physiology of Circulation. 2017; 14 (1): 31–38 (in Russ.). DOI: 10.24022/1814-6910-2017-14-1-31-38
  22. Zakharov I.P., Chomakhidze P.Sh., Kopylov F.Yu., Sultygova E.A., Mesitskaya D.F., Lyubimova E.A., Andreev D.A. Determining the risk of atrial fibrillation paroxysm in patients with chronic heart failure with intact and reduced ejection fraction. Kardiologiia. 2024; 64 (3): 25–33 (in Russ.). DOI: 10.18087/cardio.2024.3.n2466
  23. Bystrov D.O., Komarov R.N., Shonbin A.N., Afonin B.O., Sorokin R.O., Matsuganov D.A., Danachev A.O. Combined minimally invasive surgical treatment of patients with isolated left anterior descending artery lesion and atrial fibrillation. Grudnaya i Serdechno-Sosudistaya Khirurgiya. 2024; 66 (4): 508–514 (in Russ.). DOI: 10.24022/0236-2791-2024-66-4-508-514
  24. Khorkova N.Yu., Gizatulina T.P., Gorbatenko E.A., Belokurova A.V., Zabytova A.V. The role of thrombophilia gene polymorphism in patients with non-valvular atrial fibrillation and left atrial appendage thrombosis. Thrombosis, Hemostasis and Rheology 2024; 1: 21–29 (in Russ.). DOI: 10.25555/THR.2024.1.1083
  25. Gribkova I.V. Use of direct oral anticoagulants in patients with atrial fibrillation and heart defects. Thrombosis, Hemostasis and Rheology. 2024; (2): 29–38 (in Russ.) DOI: 10.25555/THR.2024.2.1096
  26. Gribkova I.V. Efficacy and safety of mono therapy with rivaroxaban in stable ischemic heart disease and atrial fibrillation. Thrombosis, Hemostasis and Rheology. 2024; (3): 13–18 (in Russ.). DOI: 10.25555/THR.2024.3.1105

About Authors

  • Sayali M. Gyulmamedova, Junior Researcher, Cardiologist; ORCID
  • Bektur Sh. Berdibekov, Senior Researcher, Cardiologist; ORCID
  • Naida I. Bulaeva, Associate Professor, Head of Department, Cardiologist; ORCID
  • Taisia S. Ryzhova, Postgraduate; ORCID
  • Agunda K. Kabisova, Junior Researcher, Cardiologist; ORCID
  • Elena Z. Golukhova, Dr. Med. Sci., Professor, Academician of RAS, Director; ORCID

Chief Editor

Elena Z. Golukhova, MD, PhD, DSc, Professor, Academician of Russian Academy of Sciences, Director of Bakoulev National Medical Research Center for Cardiovascular Surgery


Sort by